{"id":"W2049360002","doi":"10.1182/blood.v99.8.2845","title":"Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu–overexpressing cancers","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":84,"is_retracted":false,"has_abstract":true,"ca_institutions":"Research & Development Corporation","funders":"National Center for Research Resources; National Cancer Institute","keywords":"HER2/neu; Adjuvant; Medicine; Ex vivo; Cancer vaccine; Immunology; Peptide vaccine; In vivo; Granulocyte macrophage colony-stimulating factor; Dendritic cell; Immune system; Spleen; Internal medicine; Antigen; Immunotherapy; Cancer research; Cancer; Cytokine; Biology; Epitope; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002451117,0.0003332093,0.000512626,0.0002699153,0.0001509771,0.00004259124,0.0002224625,0.0002847716,0.0003745],"category_scores_gemma":[0.0001016043,0.0002602237,0.00006085625,0.0004243173,0.00003615701,0.0002444898,0.00003147031,0.0004379791,0.00007862881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002522991,"about_ca_system_score_gemma":0.000135568,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001131471,"about_ca_topic_score_gemma":0.000847507,"domain_scores_codex":[0.9981373,0.000309515,0.0004328925,0.0004100609,0.0001172958,0.0005929164],"domain_scores_gemma":[0.9989979,0.0002205346,0.0003118792,0.0003402284,0.0001065696,0.00002284822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004059214,0.001477672,0.9498277,0.0000290144,0.0002853647,0.0000239987,0.0009575685,0.0001769922,0.04087671,0.000003545358,0.000357789,0.00192446],"study_design_scores_gemma":[0.04201932,0.001875846,0.8124309,0.0006787933,0.0001031237,0.00001675574,0.0001945707,0.00001442632,0.1391662,0.000007566088,0.002967261,0.0005252783],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936163,0.005031628,0.000005746299,0.0002472046,0.0001458655,0.000483891,0.00001929885,0.00005835787,0.0003916579],"genre_scores_gemma":[0.9977896,0.0001450406,0.00005233342,0.0003161807,0.0000200848,0.00006364335,0.00005860623,0.00004748337,0.001506978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1373968,"threshold_uncertainty_score":0.999985,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004956351801242701,"score_gpt":0.192548234932947,"score_spread":0.1875918831317042,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}